Icon Plc $ICLR Shares Bought by Inspire Investing LLC

Inspire Investing LLC lifted its holdings in Icon Plc (NASDAQ:ICLR) by 85.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,983 shares of the medical research company’s stock after purchasing an additional 11,495 shares during the quarter. Inspire Investing LLC’s holdings in Icon were worth $2,765,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Sanctuary Advisors LLC increased its stake in shares of Icon by 1.1% during the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after acquiring an additional 56 shares during the period. Geneos Wealth Management Inc. lifted its position in Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the period. New Wave Wealth Advisors LLC lifted its position in Icon by 5.1% in the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares during the period. Signaturefd LLC boosted its stake in Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 72 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of Icon by 0.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after purchasing an additional 93 shares during the period. 95.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ICLR. Royal Bank Of Canada raised Icon from a “sector perform” rating to an “outperform” rating and boosted their price objective for the stock from $126.00 to $185.00 in a research note on Thursday. Barclays lifted their target price on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday. Leerink Partners set a $145.00 price target on shares of Icon in a research report on Thursday, May 28th. Bank of America upped their price target on shares of Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a report on Thursday, June 25th. Finally, Citigroup raised their price objective on shares of Icon from $140.00 to $165.00 and gave the company a “neutral” rating in a research report on Thursday. Eight analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Icon presently has an average rating of “Hold” and a consensus price target of $170.19.

Icon Stock Up 1.8%

Shares of Icon stock opened at $172.99 on Tuesday. The stock’s fifty day moving average is $130.79 and its 200-day moving average is $137.91. The firm has a market capitalization of $13.25 billion, a PE ratio of 30.78, a price-to-earnings-growth ratio of 8.38 and a beta of 1.26. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31. Icon Plc has a 12-month low of $66.57 and a 12-month high of $211.00.

Icon (NASDAQ:ICLR) last released its quarterly earnings results on Tuesday, June 23rd. The medical research company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.07. The business had revenue of $2.03 billion during the quarter, compared to analyst estimates of $1.98 billion. Icon had a return on equity of 8.73% and a net margin of 5.35%.Icon’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the company posted $3.43 EPS. Equities analysts anticipate that Icon Plc will post 9.39 earnings per share for the current year.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.